Abstract Library

#4582 Potential significance of individual dosimetry of radionuclide therapy (RLT) using [177Lu]Lu-DOTA-TATE or mixture of [177Lu/90Y]-DOTA-TATE in NET therapy

Introduction: RTL targeted somatostatin receptors is increasingly available. Individual dosimetry performed during RLT of NET may enable to achieve better results of therapy with maintaining its safety.

Conference:

Presenting Author: Opalińska M

Authors: Opalinska M, Kaminski G, Dedecjus M, Kowalska A, Kolodziej M,

Keywords: RLT, DUONEN, GEP-NET, Tandem RLT, dosimetry,

#4356 Assessment of medium- and long-term side effects of Lu-177 treatment in patients with neuroendocrine tumours

Introduction: PRRT with Lu-177 has advanced the treatment of neuroendocrine tumours (NETs), adding a valuable tool against them. This study aims to assess its long-term impact, especially on the most radio-exposed organs—kidneys and bone marrow—and the reproducibility of in vivo clinical trial results (PFS).

Conference:

Presenting Author: Salcedo Cortes S

Authors: Salcedo Cortes S, Ardila Manjarés E, Mari Hualde A, Guzman Cruz A, Casallas Cepeda M,

Keywords: Neuroendocrine tumour (NET), [177Lu]Lu-DOTATATE, Long-term side effects, Radiosensitive organs, PFS,

#4115 Neoadjuvant PRRT with 90Y-DOTATOC: Preliminary results from a monocentric perspective study

Introduction: Surgery is considered the only curative treatment for pancreatic neuroendocrine tumors (pNETs), but it is feasible only in a few patients. A new possible strategy in pNETs is preoperative PRRT, as its cytoreductive effect could increase the efficacy of surgery.

Conference:

Presenting Author:

Authors: Barone A, Grana C, Papi S, Bertani E, Rocca P,

Keywords: PRRT, 90Y-DOTATOC, Neoadjuvant PRRT, pancreatic NET,

#3792 Validation of a single time-point estimates of 177Lu-PRRT absorbed doses and impact on patient management for 192 therapies

Introduction: Dosimetry calculation after 177Lu-DOTA-TATE Peptide Receptor Radionuclide Therapy (PRRT) enables to estimate radiation doses absorbed by normal organs and target lesions. Previously, we described a newly developed model to predict absorbed doses (ADs) from a single post-treatment study with good accuracy as compared to the standard multiple time-points protocol.

Conference:

Presenting Author:

Authors: Chicheportiche A, Krausz Y, Godefroy J, Gross D, Grozinsky-Glasberg S,

Keywords: PRRT, Dosimetry, SPECT/CT, Single time-point,

#3707 Neoadjuvant PRRT with Y-90-DOTATOC – Preliminary results from a monocentric prospective study

Introduction: Surgery is considered the only curative option in pNET but is feasible only in a minority of patients. A new possible therapeutical strategy in pNETs is preoperative Peptide Receptor Radionuclide Therapy (PRRT) in order to increase the efficacy of surgery.

Conference:

Presenting Author: Grana C

Authors: Grana C, Papi S, Bertani E, Cascio A, Rocca P,

Keywords: PRRT, Y-90-Dotatoc, Neoadjuvant PRRT, pancreatic NET,